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Abstract
Background: Cyclooxygenases (COX) -1 and -2 are key mediators of the inflammatory response
in the central nervous system. Since COX-2 is inducible by inflammatory stimuli, it has been
traditionally considered as the most appropriate target for anti-inflammatory drugs. However, the
specific roles of COX-1 and COX-2 in modulating a neuroinflammatory response are unclear.
Recently, we demonstrated that COX-1 deficient mice show decreased neuroinflammatory
response and neuronal damage in response to lipopolysaccharide (LPS).
Methods: In this study, we investigated the role of COX-2 in the neuroinflammatory response to
intracerebroventricular-injected LPS (5 µg), a model of direct activation of innate immunity, using
COX-2 deficient (COX-2-/-) and wild type (COX-2+/+) mice, as well as COX-2+/+ mice pretreated
for 6 weeks with celecoxib, a COX-2 selective inhibitor.
Results:  Twenty-four hours after LPS injection, COX-2-/- mice showed increased neuronal
damage, glial cell activation, mRNA and protein expression of markers of inflammation and
oxidative stress, such as cytokines, chemokines, iNOS and NADPH oxidase. Brain protein levels of
IL-1β, NADPH oxidase subunit p67phox, and phosphorylated-signal transducer and activator of
transcription 3 (STAT3) were higher in COX-2-/- and in celecoxib-treated mice, compared to
COX-2+/+ mice. The increased neuroinflammatory response in COX-2-/- mice was likely mediated
by the upregulation of STAT3 and suppressor of cytokine signaling 3 (SOCS3).
Conclusion: These results show that inhibiting COX-2 activity can exacerbate the inflammatory
response to LPS, possibly by increasing glial cells activation and upregulating the STAT3 and SOCS3
pathways in the brain.
Introduction
Prostaglandin endoperoxide synthases or cyclooxygenases
(COX-1 and COX-2) play a central role in the inflamma-
tory cascade by converting arachidonic acid (AA), released
from membrane phospholipids by a phospholipase A2
(PLA2), into prostaglandin endoperoxide H2, which in
turn is converted to bioactive prostanoids by specific ter-
minal synthases. The two COX isoforms share 60%
homology in their amino acids sequence and have com-
parable kinetics; however they also show individual dif-
ferences. COX-1 is normally constitutively expressed in
most tissues and thought to be involved in homeostasis,
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whereas COX-2 is inducible upon inflammatory and
other stimuli [1]. However, in the central nervous system
(CNS), COX-1 and COX-2 are both constitutively
expressed and COX-2 is mainly detected in the perinu-
clear, dendritic and axonal domains of neurons, particu-
larly in cortex, hippocampus, amygdala and dorsal horn
of the spinal cord of both rodent and human CNS [2-4].
In the CNS, COX-2 has been implicated in important
physiological functions such as synaptic transmission,
neurotransmitter release, blood flow regulation, and
sleep/wake cycle [5-9].
Both COX-1 and COX-2 have been shown to play impor-
tant roles in an inflammatory response, their contribution
being different depending on the type of insult, the time
after insult, and the tissue examined [6,10]. Because COX-
2 is highly inducible by inflammatory stimuli it has been
traditionally considered as the most appropriate target for
anti-inflammatory drugs [2,11]. However, the exact role
of each COX isoform in neuroinflammation is unclear.
While we have recently reported that genetic deletion or
pharmacological inhibition of COX-1 significantly amel-
iorate the neuroinflammatory response and brain injury
following lipopolysaccharide (LPS) treatment [12], the
role of COX-2 in the neuroinflammatory process remains
controversial. For instance, COX-2 deficient (COX-2-/-)
mice have been reported to be resistant to the febrile
response induced by peripheral injection of LPS [13]. On
the other hand, selective pharmacological inhibition of
COX-2, but not of COX-1, increases the expression of sev-
eral pro-inflammatory genes in the vascular associated
cells and the parenchymal microglia after systemic injec-
tion of LPS [14].
In this study we examined the neuroinflammatory
response of COX-2-/- and wild type (COX-2+/+) mice to
intracerebroventricular (icv) injection of LPS, which is a
model of direct activation of brain innate immunity [15-
19].
LPS, a component of the outer cell wall of gram-negative
bacteria, mediates its effect through the CD14 receptor, a
glycosylphosphatidylinositol-linked membrane protein
that is present on microglial cells. The LPS-CD14 com-
plex, together with other adaptor proteins, binds to the
toll-like receptor 4 (TLR4), which is present on microglia,
but not on astrocytes, oligodendrocytes or cortical neu-
rons [20]. This initiates a bifurcated signal transduction
cascade that leads to the transcription of inflammatory
and immune response genes, primarily via nuclear factor-
κB (NF-κB) activation but also through c-Fos/c-Jun and
Janus kinase (JAK)/signal transducer and activator of tran-
scription 3 (STAT3)-dependent pathways [21]. The signal-
ing events ultimately lead to the production of free
radicals generated by NADPH oxidase, myeloperoxidase
and inducible nitric oxide synthase (iNOS) in combina-
tion with cytokines and chemokines [22,23], which are
mediators of the LPS-induced injury [15,16,24]. In this
regard, previous data suggest that interleukin-1β (IL-1β)
and tumor necrosis factor-α (TNF-α) can contribute to
neuronal death in models of acute CNS injury as well as
in chronic neurodegenerative disease [25].
In this study, we demonstrate that COX-2-/- mice are more
susceptible than COX-2+/+ mice to LPS-induced neuronal
injury and exhibit an increase in microglia and astrocyte
activation, and increases in the expression of genes and
proteins for inflammatory cytokines, chemokines, reac-
tive oxygen species-generating enzymes, such as iNOS and
NADPH oxidase, and in the expression of STAT3 and sup-
pressor of cytokine signaling 3 (SOCS3) signaling mole-
cules. COX-2+/+ mice chronically treated with celecoxib, a
COX-2 selective inhibitor, also exhibit an increased neu-
roinflammatory response compared to untreated wild-
type mice.
Materials and methods
Animals housing
Three-month-old male COX-2+/+ and COX-2-/- mice on a
C57BL/6-129/Ola genetic background were used [26].
Mice were received at our animal facility at 6 weeks of age
from a NIEHS colony maintained by Taconic Farms (Ger-
mantown, NY) with heterozygous by heterozygous breed-
ings for greater than 35 generations. In order to prevent
the inclusion of strain or genetic background confounders
between COX deficient and wild type mice, all of the mice
used in this study were progeny derived from hetero-
zygous by heterozygous mating and therefore all con-
tained the same strain and genetic background [26,27].
Mice were housed at 25°C in our animal facility with a 12
h light/dark cycle with free access to food and water. For
celecoxib pretreatment, COX-2+/+ mice were given free
access for six weeks to a diet containing 0 or 6000 ppm
celecoxib, a COX-2 specific inhibitor, as previously
described [28]. Briefly, celecoxib (Celebrex™) capsules
(400 mg; Pfizer Inc, New York, NY) were obtained from
the NIH Division of Veterinary Medicine and were incor-
porated into feed by Research Diets, Inc. (New Brunswick,
NJ). All procedures were performed under a NICHD
approved animal protocol in accordance with NIH guide-
lines on the care and use of laboratory animals.
LPS administration
Mice were anesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg, i.p.) and positioned in a stereotaxic
apparatus (Kopf Instruments, Tujunga, CA). Vehicle (ster-
ile phosphate buffer, 5 µl) or LPS (E. coli serotype 055:B5
(Sigma); 5 µg in 5 µl of sterile saline) was administered
into the cerebral lateral ventricle using a 10 µl syringe with
a 33 gauge needle (World Precision Instruments, Sarasota,Journal of Neuroinflammation 2008, 5:17 http://www.jneuroinflammation.com/content/5/1/17
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FL) and a syringe pump (Stoelting, Wood Dale, IL) at a
rate of 1 µl/min. This dose of LPS has been shown by us
and by others to produce significant neuroinflammation
when measured at 24 h [12,24,29]. The coordinates for
the sterotaxic injections were -2.3 mm dorsal/ventral, -1.0
mm lateral, and -0.5 mm anterior/posterior from the
bregma [30]. The needle was kept in this position for an
additional 5 min after injection and then retrieved slowly
from the brain.
Tissue preparation and histology
Twenty-four hours after LPS injection, mice were anesthe-
tized with sodium pentobarbital (100 mg/kg, i.p.) and
then rapidly perfused transcardially with 0.9% saline
solution containing 0.5% sodium nitrate and heparin (10
U/ml), followed by ice cold 4% paraformaldehyde in 0.1
M phosphate buffer. After transcardiac perfusions, brains
were rapidly removed, postfixed for 4 h, and then cryopro-
tected in 30% sucrose at 4°C. Frozen brains were cut into
30 µm coronal sections using a cryostat and stored at -
20°C.
Neurodegeneration was assessed using Fluoro-Jade B
(FJB), as previously described [31]. Briefly, mounted brain
sections were dried for 4 h, rehydrated through graded
concentrations of alcohol (100, 70%; 1 min each), and
rinsed for 1 min in distilled water. Sections were dipped
and shaken in potassium permanganate (0.06%) for 20
min, rinsed for 1 min in distilled water, dipped, and
shaken in a solution containing 0.004% FJB (Histochem,
Jefferson, AR), 0.1% acetic acid for 20 min. The slides were
thereafter rinsed three times in distilled water (1 min
each), dried, dipped in xylene, and coverslipped with Per-
mount mounting medium (Fisher Scientific, Ottawa,
Ontario) [31].
For immunohistochemistry, free-floating sections were
rinsed three times in phosphate-buffered saline (PBS) (10
min each) and then pretreated with PBS containing 3%
hydrogen peroxide for 10 min to block endogenous per-
oxidase activity. After PBS wash, brain sections were incu-
bated once in PBS with 0.3% Triton X-100 and once in
PBS containing 0.5% BSA for 30 min with gentle shaking.
The sections were incubated overnight at 4°C with anti-
mouse scavenger receptor A (SRA) (1:100; Serotec,
Raleigh, NC) in PBS containing 5% normal serum; fol-
lowed by treatment with a biotinylated secondary anti-
body (Vector Laboratories, Burlingame, CA) for 1 h in PBS
plus 5% normal serum at room temperature, and then
with the Vector ABC kit (Vector Laboratories) for 1 h at
room temperature. The sections were visualized with the
3,3-diaminobenzidine tetrachloride (DAB; Vector Labora-
tories, Burlingame, CA). Mounted brain sections were
dried for 4 h, dehydrated through graded concentration of
alcohol, cleared in xylene, and coverslipped with Per-
mount mounting medium (Fisher Scientific).
RNA extraction and quantitative real-time PCR
Brain total RNA was extracted using RNeasy Lipid Tissue
Midi Kit (Qiagen, Valencia, CA, USA) as directed by the
manufacturer. Total RNA extraction and reverse transcrip-
tion were performed as previously described, using the
Applied Biosystems Assay-On-Demand Gene Expression
protocol with an ABI PRISM 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA) [32-34].
Briefly, five micrograms of total RNA were reverse tran-
scribed using a High Capacity cDNA Archive kit (Applied
Biosystems). Quantitative PCR for glial fibrillary acidic
protein (GFAP), SRA1, TNF-α, IL-1β, interleukin 6 (IL-6),
CCL2/monocyte chemoattractant protein-1 (MCP-1),
CCL3/macrophage inflammatory protein 1 alpha (MIP-
1α), iNOS, the NADPH oxidase subunits gp91phox and
p67phox, mPGES-1, cPLA2, COX-1, NF-κB-P65, STAT3, and
SOCS3, was performed using specific Taqman® probes
(Applied Biosystems). Data were analyzed using the com-
parative threshold cycle (∆∆ Ct) method [35]. Results
were normalized with phosphoglycerate kinase 1 (Pgk1)
as the endogenous control, and expressed as fold differ-
ence from the vehicle injected COX-2+/+ mice.
Western blotting
Western blot analyses were carried out as described previ-
ously [33] and nuclear proteins were prepared by using a
compartmental protein extraction kit (Chemicon, Temec-
ula) according to the manufacturer's protocol. Briefly,
protein fractions were separated on Criterion gels (Bio-
Rad), blotted onto a polyvinylidene difluoride membrane
(Bio-Rad), and then immunoblotted with antibodies that
recognize p67phox  (1:500; BD Biosciences), phosphor-
ylated STAT3 (p-STAT3 (Tyr 705), 1:500, Cell signaling,
USA), STAT3 (1:1000 Cell signaling, USA), COX-1 (1:500
Cayman Chemicals, USA), and glyceraldehyde dehydro-
genase (GAPDH, 1: 2000, Santa Cruz, CA, USA) to control
for protein loading. Blotted proteins were detected and
quantified using an Odyssey Infrared Imaging System (Li-
Cor Biosciences, Lincoln, NB, U.S.A.). For IL-1β measure-
ment, a 500 µl aliquot of the crude brain homogenate was
centrifuged at 10,000 × g for 20 min at 4°C, and the super-
natant was immediately assayed using an ELISA-based kit
(mouse IL-1β/IL-1F2 Quantikine ELISA kit, R&D Biosys-
tems, Minneapolis, USA). TNF-α and MIP-1α were meas-
ured in the brain supernatant (Searchlight® Sample testing
service, Pierce Biotechnology, Woburn, MA, USA). Results
were expressed as ng/g protein.
Statistics
Data were expressed as mean ± SEM and were analyzed
with a two-way ANOVA. For Real-Time PCR results, the
two-way ANOVA was performed on the log-transformedJournal of Neuroinflammation 2008, 5:17 http://www.jneuroinflammation.com/content/5/1/17
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∆∆Ct. p values < 0.05 were considered statistically signifi-
cant.
Results
Only COX-2-/- mice show FluorojadeB positive neurons 24 
h after LPS
To address the hypothesis that LPS exerts different neuro-
toxic effects in the COX-2+/+  and COX-2-/-  mice, we
assessed neuronal damage in the brain 24 h after LPS
injection using the fluorescent marker FJB, which selec-
tively stains injured neurons [31]. LPS-injected COX-2-/-
mice (Fig. 1) showed FJB-positive cells in the hippocam-
pal area. In contrast, FJB-positive neurons were not
detected in the hippocampus of vehicle-injected mice of
each genotype and in LPS injected COX-2+/+ mice.
LPS-induced glial cell activation is increased in COX-2-/- 
mice
To determine glial cell response, we examined the expres-
sion of GFAP, a specific marker for astrocytes, and SRA, a
specific marker for phagocytic microglia [36], 24 h after
LPS injection, using quantitative real time PCR and
immunohistochemistry. LPS markedly increased the
expression of GFAP (Fig. 2A) and SRA mRNA (Fig. 2B)
compared to vehicle injected mice, and the induction was
higher in COX-2-/- than in COX-2+/+ mice.
Then we determined the immunoreactivity to SRA. In
vehicle-treated COX-2+/+  and COX-2-/-  mice, no SRA
immunoreactivity was seen (Fig. 2C). Intense immunore-
active SRA-positive microglia with enhanced staining
intensity, enlarged cell bodies, and thickening of proc-
esses were observed 24 h after LPS injection in the corti-
cal/caudate putamen and hippocampal area of COX-2+/
+mice. In LPS-injected COX-2-/- mice, SRA-positive cells
were numerous with higher cells retaining an enlarged cell
body with thickening of ramified processes (Fig. 2C).
Expression of cytokines and chemokines is increased in 
COX-2-/- mice after LPS
The expression of cytokine and chemokine genes, such as
TNF-α, IL-6, IL-1β, MIP-1α/CCL3, MCP-1/CCL2, was
determined quantitatively using real time PCR. LPS signif-
icantly increased the expression of TNF-α (Fig. 3A), IL-6
(Fig. 3B), IL-1β (Fig. 3C), MIP-1α and MCP-1 (Fig. 3E)
mRNA in both COX-2+/+ and COX-2-/- mice. However, the
mRNA levels of these cytokines were higher in the COX-2-
/-compared to COX-2+/+ mice (Fig. 3A–C and 3E). IL-1β
was almost not detectable in the brain of vehicle-injected
mice (Fig. 3D). Brain protein levels of IL-1β were also
increased after LPS in both COX-2+/+ and COX-2-/- mice,
and the increase was higher in the COX-2-/- mice (Fig. 3D).
Brain protein levels of TNF-α and of MIP-1α were also sig-
nificantly increased after LPS injection in COX-2-/-com-
pared to COX-2+/+ mice (TNF-α: 3.9 ± 0.2, LPS injected
COX-2-/- (n = 5) vs. 2.2 ± 0.6 ng/g protein, LPS injected
COX-2+/+ (n = 3); MIP-1α: 340 ± 70, LPS injected COX-2-
/-(n = 5) vs. 70 ± 41 ng/g protein, LPS injected COX-2+/+ (n
= 3), p < 0.05).
Effects of COX-2 deficiency on LPS-induced neuronal degeneration Figure 1
Effects of COX-2 deficiency on LPS-induced neuronal degeneration. Representative photomicrographs of Fluoro-
Jade-B staining in the hippocampus of COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. High magnification 
(10×) images of FluoroJade-B staining in the hippocampus are shown. The inset shows details of the neurons stained by Fluor-
oJade-B in the hippocampus of COX-2-/- mice 24 h after icv injection of LPS (40× magnification). Bars represent 100 µm.
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Effects of COX-2 deficiency on LPS-induced expression of glial markers Figure 2
Effects of COX-2 deficiency on LPS-induced expression of glial markers. Quantitative real time-PCR analysis of 
astrocyte marker GFAP (A) and microglia marker SRA mRNA (B) in COX-2+/+and COX-2-/- mice 24 h after icv injection of LPS 
or vehicle. Data are presented as mean ± SEM (n = 4-6). ***P < 0.001 compared to the corresponding vehicle-injected mice; #P 
< 0.05 compared to the LPS-injected COX-2+/+ mice. (C) Effects of COX-2 deficiency on LPS-induced activation of microglia. 
Representative photomicrographs of SRA immunohistochemistry in the striatum/caudate putamen and hippocampal area for 
COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. Bars represent 100 µm.
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Effects of COX-2 deficiency on LPS-induced expression of cytokines and chemokines Figure 3
Effects of COX-2 deficiency on LPS-induced expression of cytokines and chemokines. Quantitative real time-PCR 
analysis of TNF-α (A), IL-6 (B), IL-1β (C), and CCL3/MIP-1α and CCL2/MCP-1 (E) for COX-2+/+ and COX-2-/- mice 24 h after icv 
injection of LPS or vehicle. (D) ELISA-based quantification of IL-1β protein levels in the brain of COX-2+/+ and COX-2-/-mice 
24 h after icv injection of LPS or vehicle. Data are presented as mean ± SEM (n = 4-6). ***P < 0.001 compared to the corre-
sponding vehicle-injected mice; #P < 0.05, ##P < 0.01, ###P < 0.001 compared to the LPS-injected COX-2+/+ mice.
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mRNA expression of mPGES-1 is increased in COX-2-/- 
mice after LPS
Brain mRNA levels of mPGES-1 were significantly
increased by LPS, but the induction was significantly
higher in the COX-2-/- mice compared to COX-2+/+ mice
(Fig. 4A). In contrast, cPLA2  mRNA expression was
increased by LPS to a similar extent in both COX-2+/+ and
in COX-2-/- mice (Fig. 4B). COX-1 protein (Fig. 4C and
4D) and mRNA levels were not significantly changed by
either LPS treatment or mouse genotype (COX-2+/+ mice:
0.8 ± 0.03 LPS vs. 1.0 ± 0.07 vehicle; COX-2-/- mice: 1.5 ±
0.41 LPS vs. 0.9 ± 0.07 vehicle; p > 0.05), suggesting that
the enhanced neuroinflammatory response in COX-2-/-
mice is not mediated by a compensatory induction in
COX-1 after LPS. The expression of cPGES and mPGES-2
mRNA was not significantly different between COX-2+/+
and COX-2-/- mice after LPS injection (data not shown),
suggesting that these enzymes are not involved in the
enhanced neuroinflammatory response of COX-2-/- mice
at the time point examined.
Expression of reactive oxygen species generating enzymes 
is increased in COX-2-/- mice after LPS
iNOS and NADPH oxidase are major sources of reactive
oxygen species during the inflammatory process, and both
are expressed in glial cells. We examined gene and protein
expression of ROS-generating enzymes in COX-2-/- mice
24 h after LPS injection using quantitative real time-PCR
and Western blotting. In response to LPS, COX-2-/- mice
showed a higher increase in iNOS mRNA levels compared
Effects of COX-2 deficiency on LPS-induced expression of enzymes involved in the arachidonic acid cascade Figure 4
Effects of COX-2 deficiency on LPS-induced expression of enzymes involved in the arachidonic acid cascade. 
Quantitative real time-PCR analysis of mPGES-1 (A) and cPLA2 (B) for COX-2+/+ and COX-2-/- mice 24 h after icv injection of 
LPS or vehicle. (C) Quantification of COX-1 protein levels, relative to GAPDH internal loading control in the whole brain. (D) 
Representative immunoblot of COX-1 expression in COX-2+/+ and COX-2-/- mice 24 h after icv injection of LPS or vehicle. 
Data are presented as mean ± SEM (n = 4-6). ***P < 0.001 compared to the corresponding vehicle-injected mice; #P < 0.05 
compared to the LPS-injected COX-2+/+ mice.
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to COX-2+/+ mice (Fig. 5A). Similarly, mRNA levels of
NADPH oxidase cytosolic subunit p67phox and membrane
subunit gp91phox were significantly elevated at 24 h after
LPS injection in both genotypes compared with vehicle-
injected controls (Fig. 5B and 5C). COX-2-/- mice showed
a higher increase in the expression of p67phox and gp91phox
mRNA than COX-2+/+ mice (Fig. 5B and 5C). Western
blotting analysis confirmed that protein level of the
p67phox subunit was higher in the COX-2-/- mice compared
to the COX-2+/+ mice after LPS (Fig. 5D and 5E).
Phosphorylated STAT3 and the mRNA expression of 
STAT3 and SOCS3, but not of NF-κB, are increased in 
COX-2-/- mice after LPS
Activation of the transcription factors NF-κB and STAT3
plays a critical role in the production of inflammatory
Effects of COX-2 deficiency on LPS-induced expression of ROS-generating enzymes Figure 5
Effects of COX-2 deficiency on LPS-induced expression of ROS-generating enzymes. Quantitative real time-PCR 
analysis of iNOS (A), gp91phox (B) and p67phox mRNA (C) for COX-2+/+ and COX-2-/- mice that received icv injection of LPS or 
vehicle 24 h before sacrifice. (D) Quantification of p67phox protein levels, relative to GAPDH internal loading control in the 
whole brain. (E) Representative immunoblot of p67phox expression in COX-2+/+ and COX-2-/- mice 24 h after icv injection of 
LPS or vehicle. Data are presented as mean ± SEM (n = 4-6). ***P < 0.001 compared to the corresponding vehicle-injected 
mice; #P < 0.05, ##P < 0.01 compared to the LPS-injected COX-2+/+ mice.
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mediators by activated microglia [12]. STAT signaling is
tightly regulated by its negative regulators, suppressors of
cytokine signaling (SOCS), and is controlled by STAT
phosphorylation [37]. To determine the transcriptional
mechanism underlying the increased inflammatory
response to LPS observed in the COX-2-/- mice, we exam-
ined NF-κB p65 and STAT3 levels. The mRNA expression
of NF-κB (Fig. 6A) was increased similarly in COX-2+/+
and COX-2-/- mice after LPS. The expression of STAT3 and
SOCS3 mRNA was also significantly increased 24 h after
LPS injection in both genotypes compared to the vehicle-
injected COX-2+/+ mice (Fig. 6B and 6C), but the increase
Effects of COX-2 deficiency on LPS-induced expression of transcription factors NF-κB and STAT3, and SOCS3 Figure 6
Effects of COX-2 deficiency on LPS-induced expression of transcription factors NF-κB and STAT3, and 
SOCS3. Quantitative real time-PCR analysis of NF-κB (A), SOCS3 (B) and STAT3 mRNA (C) for COX-2+/+ and COX-2-/- mice 
24 h after icv injection of LPS or vehicle. (D) Quantification of phosphorylated STAT3 (Tyr 705) protein levels, relative to the 
total STAT3 in the brain nuclear fraction. (E) Representative immunoblot of P-STAT3 expression in COX-2+/+ and COX-2-/- 
mice 24 h after icv injection of LPS or vehicle. Data are presented as mean ± SEM (n = 4-6). *P < 0.05, **P < 0.01, ***P < 0.001 
compared to the corresponding vehicle-injected mice; ##P < 0.01 compared to the LPS-injected COX-2+/+ mice.
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was significantly higher in COX-2-/- mice than in COX-2+/
+ mice. Phosphorylated STAT3 was not detected in the
brain nuclear fraction of vehicle-injected mice (Fig. 6D
and 6E); however, after LPS, phosphorylated STAT3 pro-
tein level increased in both genotypes, but was increased
to a greater extent in COX-2-/- mice (Fig. 6D and 6E).
Effects of chronic pretreatment with celecoxib (6000 ppm for 6 weeks) on LPS-induced brain IL-1β levels, the expression of  COX-1, p67phox NADPH oxidase subunit and the phosphorylated STAT3 Figure 7
Effects of chronic pretreatment with celecoxib (6000 ppm for 6 weeks) on LPS-induced brain IL-1β levels, the 
expression of COX-1, p67phox NADPH oxidase subunit and the phosphorylated STAT3. (A) Representative immu-
noblot of COX-1 protein levels, relative to GAPDH internal loading control, in the whole brain of COX-2+/+ and celecoxib-
treated COX-2+/+ mice 24 h after icv injection of LPS or vehicle. (B) ELISA based immunoassay for brain IL-1β in celecoxib-
treated mice (n = 7) and untreated COX-2+/+ mice (n = 4). (C) Quantification of p67phox protein levels, relative to GAPDH 
internal loading control in the whole brain with representative immunoblot (D) in celecoxib-treated mice and untreated COX-
2+/+ mice (n = 4). (E) Quantification of phosphorylated STAT3 (Tyr 705) protein levels, relative to the total STAT3 in the brain 
nuclear fraction and the representative immunoblot (F) in celecoxib-treated mice and untreated COX-2+/+ mice (n = 4). All 
data are expressed as mean ± SEM. *P <0.05, **P < 0.01, ***P < 0.001 compared to the corresponding vehicle-injected mice; #P 
< 0.05, ###P < 0.001 compared to the LPS-injected COX-2+/+ mice.
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Pretreatment of COX-2+/+ mice with celecoxib for 6 weeks 
increases LPS-induced brain IL-1β level, NADPH oxidase 
subunit p67phox, and phosphorylated STAT3
Brain COX-1 protein levels were not significantly changed
by LPS treatment either in COX-2+/+  or in celecoxib-
treated mice (Fig. 7A, COX-2+/+ mice: 0.041 ± 0.009 LPS
vs. 0.033 ± 0.003 vehicle; celecoxib-treated COX-2+/+
mice: 0.043 ± 0.0.008 LPS vs. 0.038 ± 0.004 vehicle; p >
0.05). COX-2+/+ mice pretreated with celecoxib showed a
significant increase in brain IL-1β protein level after LPS,
compared to untreated mice (Fig. 7B). The protein levels
of p67phox (Fig. 7C and 7D) and phosphorylated STAT3
after LPS (Fig. 7E and 7F) were also higher in the
celecoxib-treated mice compared to untreated mice.
Discussion
In this study we demonstrate for the first time that genetic
deletion of COX-2 enhanced the neuroinflammatory
response and increased the susceptibility to neuronal
damage induced by centrally injected LPS. We also
showed that chronic treatment with a selective COX-2
inhibitor, celecoxib, also increases LPS-induced protein
levels of IL-1β, a major proinflammatory cytokine, of
phosphorylated STAT3, a transcription factor involved in
the progression of the inflammatory cascade, and of
NADPH oxidase subunit p67phox, a marker of oxidative
stress. We have previously demonstrated that this chronic
dosing paradigm of celecoxib (6000 ppm for 6 weeks)
leads to a plasma concentration of 18.2 ± 5.8 µg/ml [28].
Assuming 98% binding of celecoxib to plasma proteins
and that only free celecoxib can cross the blood brain bar-
rier [38], brain concentration of celecoxib is approxi-
mately 640 nM, well above the IC50 (39 nM) of celecoxib
for COX-2 [28]. These plasma concentrations are within
the same order of magnitude of steady state concentra-
tions (2–3 µg/ml) observed in humans after acute admin-
istration of 400–800 mg of celecoxib, doses clinically used
for the treatment of rheumatoid arthritis and familial ade-
nomatous polyposis [39].
In this study, FJB-positive neurons were only observed in
the COX-2-/-  mice, suggesting that COX-2 deletion
increases the susceptibility to LPS-induced neurodegener-
ation. There is a conflicting view about the role of COX-2
in neurodegeneration and neurotoxicity [40]. For
instance, COX-2 inhibition is believed to be neuroprotec-
tive in models such as MPTP (1-methyl 4-phenyl 1,2,3,6-
tetrahydropyridine), quisquallic acid induced damage
[41,42], and centrally injected NMDA-induced neurotox-
icity [43,44]. However, in these studies, where the toxins
directly damage neurons, COX-2-mediated cytotoxicity
does not appear to be linked to the inflammatory
response [41]. On the other hand, pre-treatment with
COX-2 inhibitors or genetic deletion of COX-2 has been
shown to increase seizure activity and neuronal damage in
response to kainate [28,45], and to exacerbate endotoxin-
induced ocular inflammation [46] and tissue damage in
ConA- and acetaminophen-induced hepatotoxicity
[47,48]. Another study reported, in support of our obser-
vations, that selective pharmacological inhibition of
COX-2 with NS-398 increases the transcription of inflam-
matory genes (mPGES-1, TLR2, CD14, MCP-1) in vascular
associated brain cells and parenchymal microglia after
systemic injection of LPS [14]. While these conflicting
data highlight the importance of investigating the distinct
roles of COX-1 and COX-2 in physiology and pathology,
our findings suggest that COX-2-derived products selec-
tively mediate a protective effect in the development and/
or the resolution of inflammation in the brain after endo-
toxin activation of the innate immune system. In this
regard, a recent review emphasizes that COX-2 mediates
neuroprotection  via  specific anti-inflammatory lipid
mediators [49]. Furthermore, Gilroy and colleagues dem-
onstrated that selective COX-2 inhibitors, by blocking the
production of PGE2 and PGD2, disturbed the resolution
phase of inflammation, leading to delay in return to
homeostasis [50].
COX-1 protein levels were not significantly changed by
LPS in either COX-2-/- or celecoxib-treated mice compared
to COX-2+/+ mice, indicating that the increased neuroin-
flammatory response was not due to an increased com-
pensatory expression of COX-1 in response to LPS when
COX-2 is either genetically abrogated or pharmacologi-
cally inhibited. Increases in microglial activation and in
the induction of cytokines and chemokines in the COX-2-
/-  mice could contribute to the susceptibility to LPS-
induced damage. Overexpression of chemokines, small
pleiotropic chemoattractant cytokines that promote leu-
kocytes activation and migration, has been recently impli-
cated in many neurological disorders including multiple
sclerosis, and Alzheimer's disease [51,52]. The overexpres-
sion of chemokines observed in the COX-2-/- mice after
LPS may increase the leukocytes and monocytes recruit-
ment in the inflamed brain and cause neuronal damages,
in the absence of a "switch off" mechanism. The increased
expression of cytokines could be due to the incapacity of
the tissue to resolve the inflammation, leading to a persist-
ent activation of the inflammatory cascade. One possibil-
ity is that COX-2 deletion or inhibition leads to a
reduction in anti-inflammatory mediators or neuro-
trophic factors, which would impair the brain ability to
resolve the inflammation.
iNOS and NADPH oxidase may also contribute to micro-
glia-mediated LPS induced neurotoxicity by increasing the
production of extracellular reactive oxygen and nitrogen
species, which, in turn, stimulate the microglial release of
pro-inflammatory mediators that, like radical oxygen spe-
cies, are toxic to neurons [53,54]. In this regard, NADPHJournal of Neuroinflammation 2008, 5:17 http://www.jneuroinflammation.com/content/5/1/17
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inhibitors suppress LPS-induced expression of iNOS, IL-6,
IL-1β and TNF-α in glial cells in vitro [55] and NADPH oxi-
dase has been shown to regulate COX-2 mediated PGE2
production in cultured microglia [56].
The JAK/STAT pathway is a key player in the intracellular
response to cytokines. SOCS3 is a potent inhibitor of the
JAK/STAT signaling cascade, negatively regulating signal
transduction pathways mediated by a variety of cytokines.
SOCS3 has been suggested to play a critical role in inte-
grating the neuroimmunoendocrine circuits [57].
Although NF-κB p65 expression were similar in COX-2+/+
and COX-2-/- mice after LPS, we found that the mRNA
expression of STAT3 and the levels of phosphorylated
STAT-3 were significantly higher in the COX-2-/- mice
compared to wild type mice. SOCS3 was also upregulated
in the COX-2-/- mice compared to COX-2+/+ mice after LPS.
SOCS3 is a negative modulator of inflammatory cytokine
signaling [58] and can be induced by inflammatory stim-
uli such as LPS, TNF-α and IL-6 [58,59]. SOCS3 mRNA
up-regulation in the COX-2 deficient mice can thus be
viewed as the consequence of the higher cytokine produc-
tion in these mice after LPS. In this regard, SOCS3 overex-
pression has been shown to lead to neuroblastoma cell
death [60]. Overall, our data indicate a dysregulation of
the cytokine signaling pathway in the COX-2-/-  mice,
which may mediate the increased neuroinflammatory
response.
While independent epidemiological studies indicate that
non steroidal anti-inflammatory drugs (NSAIDs) admin-
istration prevents or delays the onset and risk of develop-
ing Alzheimer's disease [61-63], clinical trials using COX-
2 selective inhibitors in patients with mild to severe cog-
nitive impairment, have been unsuccessful to date [64-
67], with the exception of a small double blind, placebo-
controlled study with indomethacin, a preferential COX-
1 inhibitor [68]. We have recently demonstrated that
genetic deletion or pharmacological inhibition of COX-1
significantly attenuates glial cells activation and the neu-
roinflammatory response, oxidative stress and neuronal
damage in response to icv injected LPS [12]. Our results
show that while COX-1 selective inhibition may be bene-
ficial, selective inhibition of COX-2 appears not to be ben-
eficial in neurodegenerative diseases with a marked
inflammatory component and may explain the failure of
selective COX-2 inhibitors to protect AD patients from
cognitive decline in clinical trials [64-67].
Conclusion
These findings altogether indicate that the two COX iso-
forms display opposite roles in the brain during the acute
neuroinflammatory process and that COX-2 inhibition
worsens the inflammatory response to LPS, suggesting a
neuroprotective function of COX-2-derived products. In
this regard, further investigations are warranted to identify
which specific COX-2 products may mediate the neuro-
protective effects and more research should be focused on
COX-1 selective inhibitors for the treatment of neurologi-
cal and neurodegenerative diseases with an inflammatory
component.
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